Abalo R, Vera G, López-Pérez AE et al. The gastrointestinal pharmacology of cannabinoids: focus on motility. Pharmacology. 2012;90(1-2):1-10

Bachs L, Mørland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int. 2001 Dec 27;124(2-3):200-3

Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G. Effect of delta 9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol. 2009;156:153–62

Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006 Apr 21;105(1-2):1-25

Bossong MG, Jansma JM et al. Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC). Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:53-69

Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control. 2013 Oct;24(10):1811-20

Chagas MH, Eckeli AL, Zuardi AW et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther. 2014 May 21. doi: 10.1111/jcpt.12179

Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia. 2014 Jun;55(6):787-90

Cridge BJ, Rosengren RJ. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag Res. 2013 Aug 30;5:301-13

Cunha JM, Carlini EA et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21(3):175-85

D’Argenio G, Petrosino S, Gianfrani C, et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med. 2007;85:523–30

Deiana S. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug Test Anal. 2013 Jan;5(1):46-51

Earleywine M, Bolles JR. Marijuana, expectancies, and post-traumatic stress symptoms: a preliminary investigation. J Psychoactive Drugs. 2014 Jul-Aug;46(3):171-7

Esposito G, Filippis DD, Cirillo C et al. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytother Res. 2013 May;27(5):633-6

Eubanks LM, Rogers CJ et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm. 2006 Nov-Dec;3(6):773-7

Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012 Jun 13;6:CD009270

Gordon AJ, Conley JW et al. Medical consequences of marijuana use: a review of current literature. Curr Psychiatry Rep. 2013 Dec;15(12):419

Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012 Jul;109(29-30):495-501

Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol. 2011 Aug;163(7):1447-63

Hansen HS, Artmann A. Endocannabinoids and nutrition. J Neuroendocrinol. 2008; 20 Suppl 1:94-9

Hofmann ME, Frazier CJ. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Exp Neurol. 2013 Jun;244:43-50

Hofmann ME, Frazier CJ. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Exp Neurol. 2013 Jun;244:43-50

Johnson JR, Burnell-Nugent M, Lossignol D et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010 Feb;39(2):167-79

Johnson JR, Lossignol D et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013 Aug;46(2):207-18

Joshi M, Joshi A, Bartter T. Marijuana and lung diseases. Curr Opin Pulm Med. 2014 Mar;20(2):173-9

Koehler J. Who benefits most from THC:CBD spray? Learning from clinical experience. Eur Neurol. 2014;71 Suppl 1:10-5.

Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007;9(4):413-30

Lal S, Prasad N et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6

Langford RM, Mares J, Novotna A et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013 Apr;260(4):984-97

Lee MH, Hancox RJ. Effects of smoking cannabis on lung function. Expert Rev Respir Med. 2011 Aug;5(4):537-46

Leweke FM, Piomelli D et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012 Mar 20;2:e94

Lin XH, Wang YQ et al. Role of endogenous cannabinoid system in the gut. Sheng Li Xue Bao. 2013 Aug 25;65(4):451-60

Lotan I, Treves TA et al. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol. 2014 Mar-Apr;37(2):41-4

Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011 Nov;72(5):735-44

Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014 Jun;55(6):783-6

Maccarrone M. Endocannabinoid signaling in cancer: a rather complex puzzle. Trends Pharmacol Sci. 2013 Aug;34(8):426-7

Mittleman MA, Lewis RA et al. Triggering myocardial infarction by marijuana. Circulation. 2001 Jun 12;103(23):2805-9

Naftali T, Bar-Lev Schleider L, Dotan I et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1276-1280.e1

Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J. 2013 May;280(9):1918-43

Parikh RS, Parikh SR. Alternative therapy in glaucoma management: is there any role? Indian J Ophthalmol. 2011 Jan;59 Suppl:S158-60

Passie T, Emrich HM et al. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012 Jul-Aug;4(7-8):649-59

Pletcher MJ1, Vittinghoff E, Kalhan R et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012 Jan 11;307(2):173-81

Portenoy RK, Ganae-Motan ED et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012 May;13(5):438-49

Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013 Dec;29(3):574-7

Rekand T. THC:CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol. 2014;71 Suppl 1:4-9

Robson P. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011;10(5):675-85

Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007 Sep;29(9):2068-79.

Schicho R, Storr M. Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Can J Gastroenterol. 2011 Jul;25(7):377-83

Selvarajah D, Gandhi R et al. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010 Jan;33(1):128-30

Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013 Jun;10(3):239-47

Tomida I, Azuara-Blanco A et al. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006 Oct;15(5):349-53

Wade DT, Collin C et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010 Jun;16(6):707-14

Walther S, Mahlberg R et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006 May;185(4):524-8

Zajicek JP, Hobart JC, Slade A et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32